SCHEDULE: OrbiMed Reduces Stake in Enliven Therapeutics

OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics, Inc. by more than 1%.

Summary

• OrbiMed Advisors LLC and its affiliates filed an amendment to their Schedule 13D regarding Enliven Therapeutics, Inc.
• The reporting persons sold a total of 889,478 shares on June 22, 2025, at prices of $45.38 and $45.00 per share.
• The aggregate beneficial ownership of the reporting persons decreased by more than 1% as a result of these transactions.
• The reporting persons currently hold 6,774,507 shares, representing approximately 9.5% of the outstanding common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine disclosure of a partial divestment by an institutional investor rather than a fundamental change in the company's outlook.

Positives

• The reduction in stake reflects active portfolio management by a major institutional investor.
• The shares were sold at price points of $45.00 and $45.38, indicating liquidity in the stock.

Negatives

• The reduction of a significant position by a major institutional shareholder can sometimes signal a lack of confidence or a shift in investment strategy regarding the issuer.

Risks

• Future sales by the reporting persons could exert downward pressure on the share price.
• The reporting persons reserve the right to acquire or dispose of additional shares based on market conditions and the issuer's performance.

Future Outlook

The reporting persons intend to review their investment in the Issuer periodically and may acquire or dispose of shares based on business conditions, market price, and other investment opportunities.

Management Comments

• The reporting persons have not formulated any plans or proposals relating to extraordinary corporate transactions, changes in the board, or material changes to the issuer's business structure.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is common as funds rebalance portfolios or reach target exit prices, and this move by OrbiMed is consistent with standard lifecycle management of venture-backed biotech holdings.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for beneficial owners holding over 5% of a company's equity.
• The use of a Joint Filing Agreement is standard practice for affiliated investment entities to streamline regulatory compliance.

Stakeholder Impact

• Shareholders may perceive the sale as a reduction in institutional support.
• The market may adjust the share price based on the increased supply of shares sold by the reporting persons.

Next Steps

• Continued monitoring of the issuer's business and market conditions by the reporting persons.
• Potential future filings if beneficial ownership changes by 1% or more.

Key Dates

Recommendation

The sale of shares by a major institutional investor is a signal to monitor, but without a change in the company's fundamental business strategy, a hold position is appropriate until further clarity on the issuer's performance is provided.

Keywords

Enliven Therapeutics, OrbiMed, Schedule 13D, Institutional Ownership, Biotech, Equity Transaction